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While a significant amount of clinical information has been reported concerning
intestinal involvement in Behçet’s disease (BD), esophageal involvement in BD
has not yet been studied extensively. The aim of this study was to evaluate the
prevalence of esophageal involvement in BD and its clinical characteristics. We
retrospectively reviewed the medical records of 842 patients diagnosed with BD at
a single tertiary institution in Korea between January 1990 and June 2006. Of the
842 patients with BD, 129 patients (15.3%) experienced upper gastrointestinal
symptoms that required inspection through esophagogastroduodenoscopy. Eso-
phageal involvement was found in 6 (4.7%) of the 129 patients. The activity index
of Behçet’s disease did not differ among patients with or without esophageal involve-
ment. All patients with esophageal involvement responded well to medical treat-
ment and no one experienced serious complications. The results of our study demon-
strate that the prevalence of esophageal involvement in BD is very low and that
most patients with such involvement face few complications and respond well to
medical treatment. 
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INTRODUCTION
Behçet’s disease (BD) has been recognized as a systemic
disorder of recurrent acute inflammation, characterized by
the involvement of multiple organs and resulting in oroge-
nital ulcers, uveitis, gastrointestinal ulcers, and skin lesions
(1). Its incidence is relatively high from eastern Asia to the
Mediterranean and is estimated to affect approximately 1-10
out of 10,000 people in those areas, while in U.K. and North
America, only 1-2 cases are found for every 1,000,000 peo-
ple (2). While the etiology and pathogenesis of the syndrome
are still obscure, it is thought that autoimmune mechanisms
play a role because vasculitis is the primary pathological
lesion, and circulating autoantibodies to human oral mucous
membranes are found in approximately 50% of cases (3).
The prognosis of BD varies. However, involvement of the
central nervous system, vessels, and intestines often leads to
a poor prognosis. Digestive manifestations in BD have been
reported in up to 1-60% of cases, although this rate varies
in different countries. The most frequent sites of gastroin-
testinal involvement are the ileocecal region with extension
into the ascending colon (4). While esophageal involvement
in BD is known to be very rare, anecdotal studies report eso-
phageal involvement can cause serious complications such
as strictures, bleeding, perforation, or fistulas (5, 6). Despite
a relatively high rate of intestinal involvement in Korean BD
patients (7), patterns of esophageal involvement in Korean
patients with BD remain unclear in terms of the prevalence
and clinical characteristics. Moreover, treatment response is
controversial. Some major issues have been examined for
intestinal involvement in BD, but esophageal involvement
has been not been sufficiently studied. Accordingly, in this
study, we aimed to evaluate the prevalence and clinical char-
acteristics of esophageal involvement in Korean BD patients.
MATERIALS AND METHODS
The medical records of 842 consecutive de novo BD patients
cared at Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea between January 1990 and June 2006
were retrospectively analyzed. Diagnosis of BD was based on
a combination of clinical, enodoscopic, radiologic, and patho-
logic findings. To define BD, various diagnostic criteria have
been proposed. In this study, two diagnostic criteria, suggest-
ed by the Behçet’s disease Research Committee of Japan in
1987 (8) and the International Study Group for Behçet’s dis-
ease (ISGBD) in 1990 (9), were applied. By using the classi-
fication of the Research Committee of Japan, types were cat-
egorized into ‘complete’, ‘incomplete’, and ‘suspicious’. The
other criterion, proposed by the ISGBD, was used as a sup-
plement to certify the diagnosis of BD. Demographic charac-
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sponsiveness, and complications were evaluated. Esophageal
involvement in BD was confirmed when a discrete, punched-
out ulcer, like those found in the intestines of similar patients,
was detected during endoscopic examination and other caus-
es, such as acid reflux-related, viral, or drug-induced esophagi-
tis, were ruled out. Malignant diseases such as lymphoma or
cancer were also excluded. Histological examination was per-
formed in all cases for the differential diagnosis of esophageal
ulceration. Biopsy specimens were obtained using standard-
sized biopsy forceps from both the base and the margin of
ulcerated lesions. For more accurate diagnosis of undetermined
cases, serologic tests or quantitative polymerase chain reaction
assays were additionally undertaken to exclude viral esophagi-
tis. Finally, these diagnostic processes were combined with
the responses to specific therapy for esophageal involvement
of BD and follow-up endoscopic findings. 
The activity index of BD was investigated at the timed of
esophagogastroduodenoscopy (EGD) due to upper-gastroin-
testinal symptoms. The clinical activity score was calculated
by summing of each clinical manifestation present accord-
ing to a previously proposed system (2). Statistical analyses
of the data were conducted using SPSS 12.0 computer soft-
ware (Chicago, IL, U.S.A.) for comparison of BD activity
with/without esophageal involvement. p value<0.05 were
considered statistically significant and all p values correspond
to two-sided significance tests.
This study was approved by the Institutional Review Board
of Severance Hospital and informed consent was obtained
from all patients before endoscopic examinations.
RESULTS
Among the 842 patients with BD, 129 (15.3%) patients
experienced gastrointestinal symptoms; all 129 underwent
both EGD and ileocolonoscopy. Gastrointestinal symptoms
or signs which led them to endoscopic examinations, were as
follows: abdominal pain in 58 patients (45.0%), poor oral
intake complicated with oral ulcer in 30 (23.2%), melena or
hematochezia in 32 (24.8%), chest-pain in 4 (3.1%), dys-
phagia in 4 (3.1%), and hematemesis in one patient (0.8%).
The clinical characteristics of the 129 patients are shown in
Table 1 and their endoscopic findings are listed in Table 2.
Six patients were shown to have esophageal ulcerations sug-
gestive of esophageal involvement in BD (Fig. 1). The patients
with esophageal involvement had a higher disease activity
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EGD, esophagogastroduodenoscopy; SD, standard deviation.
Total
Behçet’s 
disease
(N=129)
Intestinal
Behçet’s 
disease
(N=69)
Esophageal
ulceration of
Behçet’s 
disease (N=6)
Age 44.8±13.2 44.3±13.2 43±7.5
(2-72) (2-72) (32-53)
Male:female 55:74 33:36 2:4
Median duration from  40.0 (0-302) 39.0 (0-174) 25.5 (0-117)
diagnosis to EGD  (months)
Type
Complete 26 (20.2%) 16 (23.2%) 1 (16.7%)
Incomplete 46 (35.6%) 24 (34.8%) 3 (50.0%)
Suspicious 57 (44.2%) 29 (42.0%) 2 (33.3%)
Disease activity
Oral ulcer 129 (100%) 69 (100%) 6 (100%)
Genital ulcer 92 (71.3%) 45 (65.2%) 4 (66.7%)
Skin lesion 62 (48.1%) 35 (53.8%) 4 (66.7%)
Arthritis 42 (32.6%) 20 (29.0%) 2 (33.3%)
Uveitis 36 (27.9%) 21 (30.4%) 1 (16.7%)
Neurology 15 (11.6%) 6 (8.7%) 0
Activity index
Mean±SD 2.34±1.08 2.43±1.08 3.00±1.10
p value - 0.15 0.08
Table 1. The clinical characteristics of study subjects
Total Behçet’s 
disease (N=129)
Intestinal Behçet’s 
disease (N=69)
Esophageal ulcer 6 (4.7%) 6 (8.7%)
Gastric erosion 16 (12.4%) 9 (13.0%)
Gastric ulcer 12 (9.2%) 6 (8.6%)
Duodenal ulcer 6 (4.7%) 4 (5.9%)
Duodenitis 1 (0.8%) 1 (1.5%)
Early gastric cancer 1 (0.8%) 0
Normal 93 (72%) 49 (71%)
Table 2. The Esophagogastroduodenoscopic findings in Be-
hçet’s disease patients
Fig. 1. Esophageal involvement of Behçet’s disease. A 53-yr-old
woman with known Behçet’s disease complained of intermittent
epigastric pain. Endoscopic examination revealed a small punched-
out, active ulceration in the distal esophagus of the patient.54 S.W. Yi, J.H. Cheon, J.H. Kim, et al.
score numerically compared to those without esophageal
involvement, which had no statistical significance (p=0.08).
Other esophageal diseases found through EGD examinations
include gastroesophageal reflux disease (5 patients), esophageal
candidiasis (2 patients), hiatal hernia (2 patients), Barrett’s
esophagus (one patient), esophageal polyp (one patient), and
esophageal varices (one patient). Of the 129 patients, intesti-
nal BD was found in 69 patients (53.5%) through colono-
scopic examinations.
Clinical characteristics of esophageal involvement in BD
are given in Table 3. Esophageal ulcerations of most patients
could be controlled by proton pump inhibitors/histamine-2
receptor blockers, colchicines, and/or 5-aminosalicylic acids.
The chest pain of one patient was controlled by oral corticos-
teroids. The median follow up period of the six patients was
39.5 months (14-78 months) after the diagnosis of esophageal
ulceration. Follow-up EGD was performed on all the 6 pa-
tients. Of them, in 3 patients, active ulceration previously
noted was not found any more and the other 3 patients expe-
rienced the improvement of ulcers. No recurrence of symt-
poms occurred in all 6 patients during the follow up. More-
over, no patients experienced serious complications, such as
esophageal stricture, esophageal bleeding, or esophageal per-
forations, during follow-up.
DISCUSSION
Gastrointestinal manifestations have been known to lead to
severe morbidity in BD patients and are commonly referred
to as ‘‘Intestinal Behçet’s syndrome’’. The frequency of in-
testinal involvement in patients with BD was known to be
0-60%, with geographic differences (10). Symptomatic in-
testinal involvement is rare in Mediterranean patients with
BD, but in East Asian patients, including Koreans, intesti-
nal involvement is more common. Shimizu et al. (11) report-
ed that gastrointestinal symptoms are present in at least 50%
of the patients with BD in Japan. The intestinal lesions are
usually resistant to medical treatment and recur frequently (25-
78%) after surgical management, especially in people of West-
ern or Chinese origin (10). The terminal ileum and the cecum
are the most frequently involved parts of the gastrointestinal
tract with esophageal involvement being very rare. Esopha-
geal ulcerations in BD are diverse and nonspecific. The ulcer-
ations can be single or multiple, shallow or deep, small or
large, or clearly or unevenly marginated. Esophageal lesions
are most commonly located in the middle esophagus, although
diffuse esophagitis and stenosis have also been reported (15).
The histological aspects of esophageal ulceration in BD re-
portedly involve acute or chronic nonspecific infiltrates and
granulation tissue and fibroblasts are typically seen at the
base of the ulceration. In addition, serious complications such
as stricture, bleeding, or perforations have been rarely des-
cribed. Since the first case of esophageal ulceration of this syn-
drome was presented by Brodie and Ochsner in 1973 (12), to
date, less than 50 cases worldwide of Behçet’s patients with
esophageal ulcers have been reported. However, the actual
prevalence of esophageal involvement in BD is still uncer-
tain and the proper management of this condition has yet to
be established (13-15). Thus, the purpose of this study was
to investigate the prevalence of esophageal involvement in BD
through a large cohort study in a single tertiary institution
EGD, Esophagogastroduodenoscopy; BD, Bechçet’s disease; 5-ASA, 5-aminosalicylic acid; PPI, Proton pump inhibitor; AZA, Azathioprine; F/U, Fol-
low up.
Duration from
diagnosis of
BD to EGD
(months)
Cause 
of EGD
Histologic 
diagnosis
Site Age Sex
Duration
of F/U 
period 
after 
diag-
nosis
(months)
F/U 
EGD
(mon-
ths)
Activity
index at
diagnosis
of
Esophage
al BD
Subtype
Medications
(added)
Medica-
tions
No
1 32 F Chest pain Chronic  44 Middle 5-ASA H2 blocker, Incomplete 2 36 12
inflammation Colchicine
2 41 M Chest pain Necrotic  7 Middle 5-ASA,  Antibiotics, Incomplete 2 78 6
inflammatory Steroid Colchicine
exudate
3 53 F Abdomen pain Ulceration 117 Lower 5-ASA, Steroid PPI Complete 4 36 12
4 42 F Dysphagia Necrotic 0 Lower H2  blocker PPI Suspicious 4 52 7
inflammatory 
exudate
5 40 M Melena Chronic 64 Lower Steroid,  AZA PPI Incomplete 2 43 6
inflammation
6 50 F Poor oral intake Chronic  0 Middle Steroid, PPI Colchicine Suspicious 4 14 6
inflammation
Table 3. Characteristics of esophageal ulceration in Behçet’s diseaseand to evaluate its clinical characteristics, especially in terms
of therapeutic responsiveness and prognosis. Our study inves-
tigated the largest population ever reported, and it was found
that esophageal ulcerations were detected in only 6 of 129
BD patients (4.7%), which suggests that the prevalence of
esophageal involvement in BD is quite low. Moreover, such
involvement may not be correlated with systemic disease
activity, disease duration, disease activity, or any other aspect
of BD. Bottomley et al. (16), conducted the first prospective
study of the esophagus in patients with BD. This study in-
volved 9 patients who underwent EGD; three patients were
asymptomatic and 6 had upper gastrointestinal symptoms
at the time of endoscopy. The prevalence of esophageal invol-
vement in BD was low (11%) and non-specific, but was much
higher than that of our data. However, this rate of esophageal
involvement might be under- or overestimated because the
case number was very small and endoscopic examination was
not performed in all cases. In another anecdotal investigation,
it was suggested that the esophageal abnormalities in BD
were found rather frequently (14/21, 66.6%) and occur even
in asymptomatic patients (13). However, in this series, gross
endoscopic abnormality was detected in only one patient
(4.8%), which yields a rate that is consistent with that of
our study. Furthermore, such involvement was not associat-
ed with any other features of BD.
Because of a lack of randomized, controlled trials for treat-
ment of various manifestations of BD, the standard treatment
remains controversial. The usual initial management is com-
bined drug therapies, involving drugs such as colchicines,
non-steroidal anti-inflammatory drug (NSAIDs), glucocor-
ticosteroids, immunosuppressive, or cytotoxic medications.
For mucocutaneous lesions, colchicines and NSAIDs are
administered (17, 18). However, intestinal lesions are report-
edly difficult to treat. Furthermore, intestinal involvement
is regarded as a serious manifestation of BD, like neurologi-
cal symptoms or retinal vascultitis, and more potent drugs
are usually chosen. Sonta et al. have suggested that mesalazine
is effective for treatment of intestinal BD (19). Glucocorti-
coids and/or immunosuppressives have also proved effective
in treating intestinal BD (20). In addition, several cases and
trials reported the successful use of thalidomide, mesalazine,
and anti-TNF-α . However, at present, the appropriate treat-
ment for esophageal involvement in BD remains controver-
sial. Corticosteroids represent the major therapeutic agent,
but as stated by Brodie and Oshsner, corticosteroid therapy
may cause esophageal perforation (12). In our series, the eso-
phageal manifestations respond well to treatment with pro-
ton pump inhibitors, mesalazine, and/or colchicines. More-
over, any serious complications, such as esophageal stricture,
bleeding, or perforations, did not develop during follow-up. 
Our study has several limitations. It is a retrospective design,
which causes various investigational limitations. Moreover,
we did not perform EGD for all the patients with BD, which
may have lead to underestimation of the exact incidence of
esophageal involvement in BD. Regarding its treatment,
further research is necessary to validate the appropriate treat-
ment of esophageal involvement in BD through random-
ized prospective studies.
In conclusion, our study demonstrated that upper gast-
rointestinal symptoms are common in BD patients, but eso-
phageal involvement is very rare and serious complications
may be negligible. Moreover, the clinical characteristics of
BD with esophageal involvement seem to be similar to those
of BD without involvement.
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